Mechanism of Action
The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination.
Avelon, Bayer Pharma AG
Avelox, Bayer Pharma AG
Floxsafe, MSN Laboratories Private Limited.
M-Flox , Hetero Labs Limited
Mahaflox , Mankind Pharma Ltd
Maxim , Jamjoom Pharmaceuticals Company Limited
Micromox, Micro Labs Limited India
Milflox, Sun Pharmaceutical Industries Limited
Molox , CCL Pharma (pvt) Ltd
Moxaf , Guilin Pharmaceutical (Shanghai) Co. Ltd.
Moxi-Bio , Sava Healthcare Ltd
Moxidoc, Medisel Kenya Ltd.
Moxiget, Getz Pharma (Pvt) Limited
Moxima , Stallion Laboratories Pvt Ltd
Moximac, Macleods Pharmaceuticals Limited
Moxeque , Questa Care Inc
Plenmoxi , Unosource Pharma Ltd
Zeebact , Zest Pharma
Moxifloxacin is a fluoroquinolone antibacterial drug indicated for treating infections in adults ≥ 18 years of age caused by designated, susceptible bacteria.
- Community Acquired Pneumonia
- Skin and Skin Structure Infections: Uncomplicated and Complicated
- Complicated Intra-Abdominal Infections
- Acute Bacterial Sinusitis
- Acute Bacterial Exacerbation of Chronic Bronchitis
Known hypersensitivity to moxifloxacin or other quinolones.
ADVERSE DRUG REACTIONS:
Most common reactions (≥ 3%) were nausea, diarrhea, headache, and dizziness.
Anticoagulant effect of warfarin may be enhanced. Monitor prothrombin time/INR, watch for bleeding.
Class IA and Class III antiarrhythmics:
Proarrhythmic effect may be enhanced. Avoid concomitant use.
Clinical | Pharmacokinetic data
Routes of Administration:
Onset of Action:
Elimination Half life:
Legal Status | Dosage forms & Strengths
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
Dosage Forms | Strengths: